Moexa
Moexa is a preclinical biotechnology company focused on developing novel small molecule therapeutics targeting TGF-β SMAD3 signaling pathways for the treatment of cancer and fibrosis. With a patented technology and a global IP footprint covering over 7 billion people, Moexa aims to address unmet medical needs in multiple cancers and fibrotic diseases. Their innovative AI platform enhances drug development efficiency, allowing for quicker and cost-effective clinical trials. The company is positioned uniquely in the market as the only known small molecule SMAD3 inhibitor in advanced development, with significant pharmaceutical investment in the TGF-β therapeutic sector.
Moexa
Moexa is a preclinical biotechnology company focused on developing novel small molecule therapeutics targeting TGF-β SMAD3 signaling pathways for the treatment of cancer and fibrosis. With a patented technology and a global IP footprint covering over 7 billion people, Moexa aims to address unmet medical needs in multiple cancers and fibrotic diseases. Their innovative AI platform enhances drug development efficiency, allowing for quicker and cost-effective clinical trials. The company is positioned uniquely in the market as the only known small molecule SMAD3 inhibitor in advanced development, with significant pharmaceutical investment in the TGF-β therapeutic sector.